PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to both the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority regarding illegal market manipulation of the common stock of Scilex. The practice of manipulative or a ...

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, tod ...

PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced it has received notification that Scilex will be added to the MSCI Global Micro Cap Index as of the close of market on Friday, May 31, 2024. MSCI is a leading provider of critical decision support tools and ...

PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex. The practice of manipulative or abusive "naked short" selling or maintaining "naked short" positions ma ...

PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today sends a letter to the U.S. House of Representatives on illegal market manipulation of the common stock of Scilex. The practice of manipulative or abusive "naked short" selling or maintaining "naked short" positions ma ...

Financial Performance - Net revenue for Q1 2024 was $10,884,000, a 2.85% increase from $10,582,000 in Q1 2023[22] - Net loss for Q1 2024 was $24,377,000, compared to a net loss of $30,753,000 in Q1 2023, indicating a 20.7% improvement[22] - For the three months ended March 31, 2024, Scilex Pharma reported a net loss of $24.4 million compared to a net loss of $30.8 million for the same period in 2023, representing a 20% improvement in net loss year-over-year[169] - Net revenue for the three months ended March 31, 2024, was $10.9 million, an increase of $0.3 million compared to $10.6 million in 2023, driven by a 28% increase in gross product sales of ZTlido and the commencement of ELYXYB sales[205] Operating Costs and Expenses - Total operating costs and expenses decreased to $30,362,000 in Q1 2024 from $36,055,000 in Q1 2023, representing a reduction of 15.5%[22] - Selling, general and administrative expenses rose to $29.3 million in Q1 2024 from $28.7 million in Q1 2023, driven by increases in advisory, financing, and personnel expenses[209] - Research and development expenses rose to $3,108,000 in Q1 2024, up from $2,736,000 in Q1 2023, reflecting a 13.6% increase[22] - Research and development expenses increased to $3.1 million in Q1 2024 from $2.7 million in Q1 2023, primarily due to increased costs associated with SP-102 and ELYXYB[208] Cash and Liquidity - Cash and cash equivalents decreased to $1,818,000 as of March 31, 2024, down from $3,921,000 at the end of 2023[20] - As of March 31, 2024, the company had cash and cash equivalents of approximately $1.8 million[215] - The Company reported negative working capital of $215.0 million, with cash and cash equivalents of approximately $1.8 million[53] - The Company has an outstanding balance of $16.3 million under a Revolving Facility with eCapital Healthcare Corp. as of March 31, 2024[51] Assets and Liabilities - Total assets decreased to $91,240,000 as of March 31, 2024, from $101,309,000 at the end of 2023, a decline of 10%[20] - Total liabilities increased to $281,026,000 as of March 31, 2024, compared to $274,247,000 at the end of 2023, an increase of 2.8%[20] - As of March 31, 2024, total indebtedness is $112.5 million, down from $128.9 million as of December 31, 2023, representing a decrease of approximately 12.5%[216] Shareholder and Equity Information - The weighted average number of shares during Q1 2024 was 102,407,000, down from 141,660,000 in Q1 2023[22] - The Company entered into an ATM Sales Agreement allowing for the sale of up to $170 million of Common Stock, with 92,295 shares sold for net proceeds of approximately $0.1 million as of March 31, 2024[131] - The Company issued 4,000,000 shares of Common Stock to a law firm as Retainer Shares for legal services[147] - As of March 31, 2024, there were 20,129,644 shares of Common Stock reserved for future issuance under the 2022 Equity Incentive Plan[137] Product Development and Commercialization - Scilex Holding Company focuses on non-opioid pain management products, with five wholly owned subsidiaries and a business combination with Vickers completed in November 2022[28] - The company launched ELYXYB in April 2023, a first-line treatment for migraines, and expects to commercialize GLOPERBA in the U.S. in the first half of 2024[29] - Scilex is developing three product candidates: SP-102, SP-103, and SP-104, with significant efforts on commercialization of ZTlido, GLOPERBA, and ELYXYB in 2024[30] - The company has a development pipeline that includes three product candidates: SP-102 (SEMDEXA), SP-103, and SP-104, with SP-102 having completed a pivotal Phase 3 study[180] Legal and Regulatory Matters - The Company entered into a settlement agreement with Virpax Pharmaceuticals, which includes an initial payment of $3.5 million and potential future royalty payments of 6% on certain drug candidates[158] - Scilex Pharma is involved in ongoing litigation regarding patent infringements related to ZTlido, with a trial scheduled for July 8, 2024[160] Debt and Financing - The Company fully repaid $25 million in Convertible Debentures in March 2024[50] - The Company entered into a Yorkville SPA to issue Convertible Debentures up to $25.0 million, with $10.0 million funded on March 21, 2023, and subsequent tranches funded in April 2023[80] - The outstanding principal balance of the Oramed Note is $92.9 million as of March 31, 2024, reduced from $96.9 million as of December 31, 2023[217] Miscellaneous - The Company has an accumulated deficit of $514.6 million as of March 31, 2024[53] - The Company recorded goodwill of $13.5 million as of March 31, 2024, with no impairment recognized during the three months ended March 31, 2024[78] - The Company recorded a loss of $0.5 million attributed to warrant liabilities for the three months ended March 31, 2024[67]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) (I.R.S. Employer Identification No.) (650) 516-4310 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incorp ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Presents Scilex's unaudited financial statements, showing increased net loss from higher expenses and a 'going concern' warning [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Assets slightly decreased to $86.1 million, while liabilities significantly increased to $75.0 million, reducing equity to $11.1 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $5,069 | $2,184 | | Total current assets | $31,104 | $29,608 | | Goodwill | $13,481 | $13,481 | | Total assets | $86,051 | $86,527 | | **Liabilities & Equity** | | | | Accrued rebates and fees | $35,629 | $30,893 | | Convertible debentures | $9,600 | $0 | | Total current liabilities | $64,602 | $44,842 | | Total liabilities | $74,975 | $50,288 | | Total stockholders' equity | $11,076 | $36,239 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net revenue increased to $10.6 million, but net loss significantly widened to $30.8 million due to higher SG&A and derivative liability loss Statement of Operations Highlights (in thousands, except per share data) | Account | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net revenue | $10,582 | $6,812 | | Cost of revenue | $3,591 | $1,144 | | Selling, general and administrative | $28,701 | $10,908 | | Loss from operations | $(25,473) | $(8,806) | | Loss (gain) on derivative liability | $5,253 | $(7,500) | | **Net loss** | **$(30,753)** | **$(9,143)** | | Net loss per share | $(0.22) | $(0.07) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations improved to $7.7 million, with financing providing $10.6 million, increasing cash to $5.1 million Cash Flow Highlights (in thousands) | Activity | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net cash used for operating activities | $(7,744) | $(10,731) | | Net cash proceeds from financing activities | $10,629 | $39,960 | | Net change in cash and cash equivalents | $2,885 | $29,229 | | **Cash and cash equivalents at end of period** | **$5,069** | **$33,567** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail operations, liquidity, and financing, highlighting a 'going concern' doubt due to significant losses and reliance on equity and debenture funding - The company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products. Its commercial products include **ZTlido**, **GLOPERBA**, and **ELYXYB**[26](index=26&type=chunk)[27](index=27&type=chunk) - Management has concluded that conditions such as negative working capital (**$33.5 million**), operating losses (**$25.5 million** for the quarter), and an accumulated deficit (**$406.7 million**) raise substantial doubt about the Company's ability to continue as a going concern[44](index=44&type=chunk)[46](index=46&type=chunk) - In February 2023, the company acquired the rights to **ELYXYB** (celecoxib oral solution) for the acute treatment of migraine in the U.S. and Canada. The company launched ELYXYB in the U.S. in April 2023[27](index=27&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - In March 2023, the company entered into a securities purchase agreement to issue up to **$25.0 million** in convertible debentures. As of March 31, 2023, **$10.0 million** in principal amount had been issued for net proceeds of **$9.6 million**[43](index=43&type=chunk)[67](index=67&type=chunk) - The company has two standby equity purchase agreements with Yorkville and B. Riley, each allowing the company to sell up to **$500.0 million** of its common stock, subject to certain conditions[41](index=41&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, noting increased revenue but a widened net loss due to higher expenses, and addresses liquidity concerns with new financing [Overview](index=24&type=section&id=Overview) Scilex focuses on non-opioid pain management with commercial products and a pipeline, but faces significant losses and requires substantial funding - Commercial products include **ZTlido**, **GLOPERBA** (planned 2023 launch), and **ELYXYB** (launched April 2023)[118](index=118&type=chunk) - The development pipeline includes **SEMDEXA** (Phase 3), **SP-103** (Phase 2), and **SP-104** (Phase 2 expected in 2023). Both SEMDEXA and SP-103 have received FDA Fast Track designation[119](index=119&type=chunk) - The company had a net loss of **$30.8 million** for Q1 2023 and an accumulated deficit of **$406.7 million** as of March 31, 2023[122](index=122&type=chunk) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Net revenue increased to $10.6 million, but operating loss grew to $25.5 million and net loss to $30.8 million, primarily due to higher SG&A Comparison of Results of Operations (in thousands) | Metric | Q1 2023 | Q1 2022 | Change | | :--- | :--- | :--- | :--- | | Net revenue | $10,582 | $6,812 | $3,770 | | Cost of revenue | $3,591 | $1,144 | $2,447 | | Research and development | $2,736 | $2,631 | $105 | | Selling, general and administrative | $28,701 | $10,908 | $17,793 | | Loss from operations | $(25,473) | $(8,806) | $(16,667) | | **Net loss** | **$(30,753)** | **$(9,143)** | **$(21,610)** | - The **$3.8 million** increase in net revenue was driven by a **49%** increase in gross product sales of **ZTlido**, offset by higher rebates[142](index=142&type=chunk) - SG&A expenses increased by **$17.8 million**, primarily due to higher legal expenses (**$5.1M**), personnel costs (**$4.2M**), consulting fees (**$3.3M**), and a bad debt reserve for a receivable from Sorrento (**$1.4M**)[146](index=146&type=chunk) - R&D expenses increased slightly by **$0.1 million** to **$2.7 million**, attributed to costs for SP-103, SP-104, GLOPERBA, and ELYXYB, offset by a decrease in SP-102 costs[145](index=145&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company had **$5.1 million** cash and **$406.7 million** accumulated deficit, raising substantial doubt about its going concern ability, relying on equity and debenture funding - As of March 31, 2023, the company had cash and cash equivalents of approximately **$5.1 million** and an accumulated deficit of **$406.7 million**[122](index=122&type=chunk)[151](index=151&type=chunk) - The company has concluded there is substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and substantial cumulative net losses[168](index=168&type=chunk)[218](index=218&type=chunk) - The company has entered into two Standby Equity Purchase Agreements (with Yorkville and B. Riley), each providing the right to sell up to **$500.0 million** of common stock[158](index=158&type=chunk)[159](index=159&type=chunk) - In March and April 2023, the company issued a total of **$25.0 million** in convertible debentures to Yorkville to provide liquidity[124](index=124&type=chunk)[125](index=125&type=chunk)[161](index=161&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes in market risk occurred during the first quarter of 2023 compared to the Annual Report on Form 10-K - There have been no material changes in the company's market risk during the first quarter of 2023[182](index=182&type=chunk) [Item 4. Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were ineffective due to a material weakness in accounting resources, with remediation efforts ongoing - Management concluded that as of March 31, 2023, the company's disclosure controls and procedures were not effective at a reasonable assurance level[183](index=183&type=chunk) - The ineffectiveness is due to a material weakness identified as of December 31, 2022, related to a lack of sufficient accounting resources with appropriate experience and technical expertise[184](index=184&type=chunk) - Remediation efforts, including hiring personnel and engaging consultants, are ongoing, but the material weakness has not been fully remediated as of March 31, 2023[185](index=185&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in material legal proceedings, including false advertising, non-compete, and patent infringement lawsuits - **Sanofi-Aventis & Hisamitsu Litigation:** Scilex sued two manufacturers of OTC lidocaine patches for false advertising and unfair competition. The trial is scheduled for December 2023[103](index=103&type=chunk) - **Former Employee Litigation:** Scilex sued its former President, Anthony Mack, and his new company, Virpax, for breach of a non-compete agreement. The case has been tried and is awaiting a court decision[104](index=104&type=chunk) - **ZTlido Patent Litigation:** Scilex sued Apotex for infringing on ZTlido patents after Apotex filed an ANDA for a generic version. A 30-month stay prevents Apotex from selling a generic version until at least November 2024, with a trial scheduled for June 2024[105](index=105&type=chunk) [Item 1A. Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) Outlines significant risks including limited operating history, substantial losses, going concern doubt, reliance on ZTlido, supply chain, clinical trials, IP, regulation, and Sorrento's bankruptcy [Risks Related to Limited Operating History, Financial Condition and Capital Requirements](index=40&type=section&id=Risks%20Related%20to%20our%20Limited%20Operating%20History%2C%20Financial%20Condition%20and%20Capital%20Requirements) The company faces substantial risks from limited operating history, significant losses, going concern doubt, dependence on ZTlido, and a material weakness in financial reporting - The company has a limited operating history, is heavily dependent on the commercial success of **ZTlido**, and has incurred significant losses, with an accumulated deficit of **$406.7 million** as of March 31, 2023[201](index=201&type=chunk)[204](index=204&type=chunk)[208](index=208&type=chunk) - Recurring losses, negative cash flows, and substantial net losses raise substantial doubt about the company's ability to continue as a going concern[218](index=218&type=chunk) - A material weakness in internal control over financial reporting was identified, related to a lack of sufficient accounting resources, which could lead to failure to timely and accurately report financial results[221](index=221&type=chunk)[222](index=222&type=chunk) [Risks Related to Commercial Operations and Product Development](index=44&type=section&id=Risks%20Related%20to%20our%20Commercial%20Operations%20and%20Product%20Development) Significant operational risks include reliance on single-source suppliers, third-party clinical trials, uncertain regulatory approval, intense competition, and challenges in securing payor coverage - The company relies on sole or single-source suppliers and manufacturers for its products, including an exclusive reliance on Oishi and Itochu for **ZTlido** and **SP-103**. Loss of these suppliers would be detrimental[225](index=225&type=chunk)[227](index=227&type=chunk) - The company relies on third parties to conduct clinical trials, and if these parties do not perform, it could delay or prevent regulatory approval for product candidates[241](index=241&type=chunk) - The company faces significant competition from other prescription patches, generic products, and OTC lidocaine patches[269](index=269&type=chunk) - Failure to obtain or maintain adequate coverage and reimbursement from third-party payors for **ZTlido**, **GLOPERBA**, and **ELYXYB** could significantly decrease the ability to generate revenue[276](index=276&type=chunk) [Risks Related to Intellectual Property](index=60&type=section&id=Risks%20Related%20to%20our%20Intellectual%20Property) Business heavily relies on in-licensed IP for ZTlido, SP-103, and GLOPERBA, facing risks of patent challenges, invalidation, and costly litigation to enforce or defend IP rights - The business is substantially dependent on intellectual property in-licensed from Oishi and Itochu for **ZTlido** and **SP-103**. The licensors have the right to terminate the agreement under certain conditions, which could cause Scilex to lose all rights to these products[341](index=341&type=chunk)[344](index=344&type=chunk) - The company is party to a license agreement with Romeg for **GLOPERBA**, and termination of this agreement would harm its ability to commercialize the product[345](index=345&type=chunk) - The company may not be able to obtain or maintain sufficient patent protection for its products, and existing patents may be challenged, invalidated, or held unenforceable, particularly by generic drug manufacturers[350](index=350&type=chunk)[353](index=353&type=chunk) - The company may become involved in expensive and time-consuming lawsuits to protect its patents (like the current **ZTlido** patent litigation) or defend against claims that it infringes on third-party IP[364](index=364&type=chunk)[376](index=376&type=chunk) [Risks Related to Government Regulations](index=78&type=section&id=Risks%20Related%20to%20Government%20Regulations) The company faces lengthy, costly, and unpredictable FDA approval processes, ongoing regulatory review, and risks from healthcare reform and complex fraud and abuse laws - The FDA regulatory approval process is lengthy, time-consuming, and unpredictable. There is no guarantee that product candidates like **SEMDEXA** will be approved[425](index=425&type=chunk) - The company may seek approval for its candidates via the 505(b)(2) pathway, but if the FDA disagrees or requirements change, the approval process could be longer and more costly[429](index=429&type=chunk) - Approved products are subject to continuous and extensive regulatory review, and failure to comply can result in fines, recalls, or withdrawal of approval[432](index=432&type=chunk)[433](index=433&type=chunk) - The company is subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act), and violations can lead to substantial civil and criminal penalties[459](index=459&type=chunk) [Risks Related to our Relationship with Sorrento](index=93&type=section&id=Risks%20Related%20to%20our%20Relationship%20with%20Sorrento) Scilex faces significant risks from its majority shareholder, Sorrento, including conflicts of interest, impacts from Sorrento's Chapter 11 bankruptcy, and potential liquidation of its controlling stake - Certain directors and officers have positions with both Scilex and its majority shareholder, **Sorrento**, creating potential conflicts of interest[488](index=488&type=chunk)[489](index=489&type=chunk) - **Scilex** is controlled by **Sorrento**, which holds approximately **51.9%** of the voting power. Sorrento's interests may differ from those of other public stockholders[496](index=496&type=chunk) - On February 13, 2023, **Sorrento** filed for Chapter 11 bankruptcy protection. While **Scilex** is not a debtor, this may impair the relationship and limit Scilex's operational flexibility due to Bankruptcy Court oversight[503](index=503&type=chunk)[504](index=504&type=chunk) - If **Sorrento's** case is converted to Chapter 7, it may be required to liquidate its assets, which includes its ownership stake in **Scilex**[506](index=506&type=chunk) [Risks Related to Ownership of our Common Stock](index=98&type=section&id=Risks%20Related%20to%20Ownership%20of%20our%20Common%20Stock) Ownership of common stock involves high risk, including potential price decline from future share sales, no expected dividends, worthless warrants, and reduced reporting due to 'emerging growth' and 'controlled company' status - Future sales of a substantial number of shares, including those from the dividend by **Sorrento**, may cause the stock price to decline once lock-up restrictions end[516](index=516&type=chunk)[517](index=517&type=chunk) - The company's warrants, with an exercise price of **$11.50**, may expire worthless if the stock price remains below this level. The terms of the warrants can also be amended with majority holder approval[558](index=558&type=chunk)[559](index=559&type=chunk) - The company is a 'controlled company' under Nasdaq rules due to **Sorrento's** majority ownership, qualifying it for exemptions from certain corporate governance requirements[546](index=546&type=chunk) - The company is an 'emerging growth company' and may take advantage of reduced reporting requirements, which could make its stock less attractive to some investors[543](index=543&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=109&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) On February 13, 2023, the company issued **4,000,000** common shares to Paul Hastings LLP as a retainer for legal services, exempt from registration - On February 13, 2023, **Scilex** issued **4,000,000** shares of Common Stock to law firm Paul Hastings LLP as a retainer for legal services[563](index=563&type=chunk) - The issuance was an unregistered sale, relying on the exemption from registration provided by Section 4(a)(2) of the Securities Act[563](index=563&type=chunk) [Item 3. Defaults Upon Senior Securities](index=109&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon its senior securities during the period - None[564](index=564&type=chunk) [Item 4. Mine Safety Disclosures](index=109&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[565](index=565&type=chunk) [Item 5. Other Information](index=109&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this item - None[566](index=566&type=chunk) [Item 6. Exhibits](index=110&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Quarterly Report on Form 10-Q, including business combination, financing agreements, and officer certifications - Lists various agreements including the Amended and Restated Standby Equity Purchase Agreement and the Securities Purchase Agreement with Yorkville[567](index=567&type=chunk) - Includes certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[570](index=570&type=chunk)